Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 2, 2017, Pages 208-215

  Heise, Tim ^a   Zijlstra, Eric ^a   Nosek, Leszek ^a   Rikte, Tord ^b   Haahr, Hanne ^b  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

insulin pump therapy; pharmacodynamics; pharmacokinetics; type 1 diabetes

Indexed keywords

INSULIN; INSULIN ASPART; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFUSION RATE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; INSULIN INFUSION; LEAST SQUARE ANALYSIS; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN ASPART; INSULIN INFUSION SYSTEMS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED;

EID: 85006511291     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12803     Document Type: Article

References (29)

1. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77:280-285.
2. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780-788.
3. Hermansen K, Bohl M, Schioldan AG. Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience. Drugs. 2016;76:41-74.
4. Kalra S, Gupta Y. Ultra-fast acting insulin analogues. Recent Pat Endocr Metab Immune Drug Discov. 2014;8:117-123.
5. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6:728-742.
6. Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32:21-39.
7. Thabit H, Hovorka R. Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opin Drug Deliv. 2016;13:389-400.
8. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157:336-347.
9. Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices. 2016;13:57-69.
10. Food and Drug Administration. Inactive ingredient search for approved drug products. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. Accessed October 21, 2016.
11. Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682-688.
12. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev. 2004;20:178-188.
13. Bode BW. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro and glulisine. Endocr Pract. 2011;17:271-280.
14. Benesch C, Heise T, Klein O, Heinemann L, Arnolds S. How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device. J Diabetes Sci Technol. 2015;9:792-800.
15. American Diabetes Association. Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycaemia. Diabetes Care. 2005;28:1245-1249.
16. Fieller EC. Some problems in interval estimation. J R Stat Soc Series B Stat Methodol. 1954;16:175-185.
17. Bode B, Hyveled L, Tamer SC, Ybanez P, Demissie M. Improved postprandial glycemic control with faster-acting insulin aspart in subjects with type 1 diabetes using CSII. Diabetes. 2015;64(suppl 1):A253 (Poster 994-P).
18. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-885.
19. Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27:79-84.
20. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34:2508-2514.
21. Russell-Jones D, Bode B, de Block C, et al. Double-blind mealtime faster-acting insulin aspart vs insulin aspart in basal–bolus improves glycemic control in T1D: the onset® 1 trial. Diabetes. 2016;65(suppl 1):A77.
22. Cengiz E. Closer to ideal insulin action: ultra fast acting insulins. Panminerva Med. 2013;55:269-275.
23. Maahs DM, Horton LA, Chase HP. The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther. 2010;12:S59-S65.
24. Heise T, Haahr H, Jensen L, Erichsen L, Hompesch M. Faster-acting insulin aspart improves postprandial glycemia vs insulin aspart in patients with type 1 diabetes mellitus (T1DM). Diabetes. 2014;63(suppl 1):A34.
25. Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care. 2015;38:1008-1015.
26. Buckley ST, Kildegaard J, Høiberg-Nielsen R, et al. Mechanistic analysis into the mode(s) of action of niacinamide in faster-acting insulin aspart. Diabetes Technol Ther. 2016;18(suppl 1):A116-A117.
27. Regittnig W, Urschitz M, Lehki B, et al. Absorption kinetics of insulin following subcutaneous bolus administration with different bolus durations. Diabetes. 2013;62(suppl 1):A247 (Poster 966-P).
28. Jain L, Parks MH, Sahajwalla C. Determination of time to onset and rate of action of insulin products: importance and new approaches. J Pharm Sci. 2013;102:271-279.
29. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia. 2008;51:1790-1795.